Personalized cancer therapy, which provides tailored treatments based on a patient’s specific characteristics (e.g., genetic status), has shown great promise for improving outcomes for cancer patients. Meanwhile, hundreds of clinical trials are investigating drugs targeting specific tumor genetic alterations. Melax Tech developed a CLAMP-based system for extracting genetic alteration information for personalized cancer therapy from ClinicalTrials.gov.
